Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression
2020 · New England Journal of Medicine · 523 citations
https://doi.org/10.1056/nejmoa1904398
G
Gary Richmond
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
59
Papers
4.9K
Citations
27
h-index
34
i10-index
Gary Richmond is an academic researcher from Broward Health Medical Center. The author has contributed to research in topics: HIV/AIDS drug development and treatment & HIV Research and Treatment & HIV/AIDS Research and Interventions. The author has an h-index of 27, co-authored 51 publications.
Papers by this author
worksLong-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial
2017 · The Lancet · 492 citations
https://doi.org/10.1016/s0140-6736(17)31917-7
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
2020 · The Lancet · 342 citations
https://doi.org/10.1016/s0140-6736(20)32666-0
Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection
2022 · New England Journal of Medicine · 270 citations
https://doi.org/10.1056/nejmoa2115542
Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain
2018 · PLoS ONE · 163 citations
https://doi.org/10.1371/journal.pone.0190487
Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials
2020 · JAIDS Journal of Acquired Immune Deficiency Syndromes · 137 citations
https://doi.org/10.1097/qai.0000000000002466
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat